[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"arrhythmias-cardiac\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:arrhythmias-cardiac":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,29,0,25,[9,48,70,104,125,156,183,214,240,268,293,334,353,387,414,444,471,506,535,565,595,624,646,665,701],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":47},"100641807","volta-medical-ai-software-in-real-world-during-af-ablation-100641807",false,"NCT07621055","VOLta Medical AI-software in REal-World During AF Ablation","Real-World Experience of Volta Medical AI-software During AF Ablation Using Next-generation Mapping and Ablation Technologies","VOLTAIRE-AF","Inclusion Criteria:\n\n1. Patient aged 18 years or older.\n2. Patient candidate for catheter ablation to treat paroxysmal or persistent atrial fibrillation, atrial tachycardia, de novo or after one or several previous ablation procedures, and for which the investigator considers using Volta AF-Xplorer II.\n3. Patient able and willing to provide written informed consent to participate in the study.\n4. Only for France: Patient affiliated to the French social security system.\n\nExclusion Criteria:\n\n1. Contraindication to AF\u002FAT catheter ablation using RF and\u002For PFA.\n2. Patient who is or could potentially be pregnant.\n3. Person deprived of liberty or under guardianship.\n4. Person unable to undergo a medical monitoring for geographical, social or psychological reasons.\n5. Patient's refusal to participate in the study.\n6. Enrollment in a premarket clinical study evaluating device, drug or biologic product.","ALL","18 Years",{"count":21,"type":22},150,"ESTIMATED","OBSERVATIONAL","This PMCF study \"VOLTAIRE-AF\" will allow to observe acute and long-term safety and performance outcomes of the last generation of Volta Medical AI software (Volta AF-Xplorer II) during AF ablation using next-generation mapping and ablation technologies over a 24-month follow-up and in \"real life\"clinical practice, without any imposed clinical workflow.",[26,27,28],"Atrial Fibrillation","Atrial Arrhythmia","Arrhythmias, Cardiac",[30,31,32,33,34,35,27],"Volta AF-Xplorer II","Artificial Intelligence","Cardiac ablation","Medical Device","Software","Volta Medical","RECRUITING","2026-06-17",{"date":39,"type":40},"2026-06-22","ACTUAL",{"date":42,"type":40},"2026-06-16",{"date":44,"type":22},"2030-06",{"name":35,"class":46},"INDUSTRY",3,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100420135","an-observational-post-marketing-study-using-commercially-approved-biosense-webster-bwi-medical-devices-for-the-treatment-of-participants-with-cardiac-arrhythmias-100420135","NCT04750798","An Observational Post-marketing Study Using Commercially Approved Biosense Webster (BWI) Medical Devices for the Treatment of Participants With Cardiac Arrhythmias","An Observational Post-marketing Study for Evaluation of Ongoing Safety and Effectiveness of Catheter Mapping and Ablation Using Commercially Approved BWI Medical Devices for the Treatment of Patients With Cardiac Arrhythmias","SECURE","Inclusion criteria\n\n* Diagnosed with paroxysmal or persistent Atrial Fibrillation (AF) or supraventricular tachycardia (SVT) or ventricular tachycardia (VT) and scheduled to undergo an ablation procedure for management of their arrhythmia with a per-protocol defined BW therapeutic catheter\n* Able and willing to comply with all pre, post and follow-up testing and requirements as per hospital standard of care\n* Signed patient informed consent form (ICF) as applicable per local regulation\n\nExclusion criteria:\n\n* Currently participating in an interventional (drug, device, biologic) clinical trial\n* Life expectancy of less than 12-months\n* Presenting any contraindication for the use of BWI commercially approved medical devices, as indicated in the respective user manuals",{"count":57,"type":22},8000,"The purpose of this study is to prospectively collect clinical data evaluating the ongoing safety and performance during routine-use standard cardiac arrhythmia mapping and\u002For ablation procedures while using commercial Biosense Webster Inc. (BWI) medical devices. Data generated from the study will be used to confirm safety and performance of BWI medical devices in the marketed phase and to expand the body of evidence on the use of these devices and techniques in treatment of cardiac arrhythmias.",[28],"2026-06-04",{"date":62,"type":40},"2026-06-05",{"date":64,"type":40},"2021-02-22",{"date":66,"type":22},"2037-12-31",{"name":68,"class":46},"Biosense Webster, Inc.",40,{"id":71,"slug":72,"hasResults":12,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":103},"100588208","exercise-activity-intervention-with-sensor-based-engagement-in-patients-with-atrial-fibrillation-100588208","NCT06938412","Exercise Activity Intervention With Sensor-Based Engagement in Patients With Atrial Fibrillation","Exercise Activity Intervention With Sensor-Based Engagement in Patients With Atrial Fibrillation (EASE-AF)","EASE-AF","Inclusion Criteria:\n\n* ≥40years of age\n* Paroxysmal AF\n* Electrocardiographic (or equivalent) documentation of AF within 12 months (would need to have evidence of AF after initial post-ablation blanking period if the patient had prior AF ablation)\n* AF Severity Scale (AFSS) symptom score 13-26\n* Self-report weekly moderate-vigorous physical activity (MVPA) 30-120 minutes\n\nExclusion Criteria:\n\n* Unable to give consent\n* ≤90 days from AF ablation, coronary revascularization, heart failure hospitalization\n* Left ventricular ejection fraction (LVEF) \\\u003C50%, moderate to severe stenotic valvular heart disease or severe regurgitant valvular disease or history of mechanical valve replacement, presence of implanted pacemaker or defibrillator system\n* Labile INR or unable to take anticoagulant despite indication\n* Life expectancy \\\u003C 1 year\n* Hemodialysis; severe pulmonary or liver disease\n* Musculoskeletal, balance\u002Fgait issues, severe peripheral vascular disease, or neuropathy or other neurologic conditions limiting exercise\n* Self-report MVPA \\\u003C30 minutes\n* Upon initial screening, if the participant's baseline FitBit-measured MVPA ≥180 minutes\u002Fweek (despite self-report range of 30-120 minutes), the participant will be further excluded.",{"count":79,"type":22},120,"INTERVENTIONAL",[82],"NA","Atrial fibrillation (AF) affects 1 in 4 individuals during their lifetime and continues to increase in frequency and impact. Exercise intervention has established benefits to improve AF symptoms and burden in clinical studies. However, lack of access to exercise programs has limited therapeutic adoption. The growth of technology-driven health care and diagnostics, recognized as an emerging priority by the American Heart Association, offers an opportunity for a pragmatic and patient-centered approach to meet this need. EASE-AF is a prospective, interventional study with a sequential run-in control to evaluate if a digital health-driven, patient-centered exercise intervention improves AF symptoms and burden. The research team will enroll 120 patients with symptomatic, paroxysmal AF. The main impact of this study will be the establishment of evidence for a novel, pragmatic paradigm for a patient-centered, digital technology-driven personalized exercise intervention for patients with AF.",[26,28,85],"Cardiovascular Diseases",[26,87,88,89,90,91,92],"Physical Activity","Exercise","Digital Health Intervention","Wearable Technology","Symptoms","Quality of Life","2026-05-19",{"date":95,"type":40},"2026-05-22",{"date":97,"type":22},"2026-06-01",{"date":99,"type":22},"2027-03-31",{"name":101,"class":102},"Icahn School of Medicine at Mount Sinai","OTHER",1,{"id":105,"slug":106,"hasResults":12,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":118,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":103},"100474012","testing-virtues-patient-care-sets-in-cardiac-patients-virtues-cardiac-care-100474012","NCT05452356","Testing VIRTUES Patient Care Sets in Cardiac Patients (VIRTUES Cardiac Care)","Testing of Patient Care Sets and Management of Cardiovascular Conditions Using a Virtual Platform","VIRTUES-CC","Inclusion Criteria:\n\n* Any patient with a cardiovascular condition.\n* Ability to provide informed consent.\n* Proficient in the English language.\n* Access to a device capable of running mobile application.\n* Used mobile technology within the past 3 months.\n\nExclusion Criteria:\n\n* Any medical condition making 1-month survival unlikely.",{"count":113,"type":22},2000,"Patients with various cardiac conditions (such as those who experience a heart attack) are increasing in Canada and are in need of appropriate cardiac rehabilitation and care. Many patients do not have access to local in-person cardiac clinics, particularly in rural regions of Canada. A user-friendly digital application with accessible educational resources and recommendations based on the most up to date clinical practice guidelines can help mitigate these issues. VIRTUES is a digital healthcare application that targets 11 modifiable modules as follows:\n\n1. antithrombotic management\n2. lipid management\n3. rate and rhythm control for atrial fibrillation\n4. heart failure care\n5. post myocardial infarction care\n6. blood sugar management\n7. blood pressure management\n8. physical activity\n9. healthy eating\n10. smoking cessation\n11. alcohol reduction\n\nOf the 11 total modules, the first 7 listed provide recommendations in VIRTUES. The remaining 4 (physical activity, healthy eating, smoking cessation and alcohol reduction) consist of simple referrals to existing recommendations (i.e., for healthy eating and physical exercise) and referrals to existing local programs (i.e., for smoking cessation and alcohol reduction). Thus, in this cohort study, the investigators will test the primary 7 modules with 200 patients per module for approximately one month each in order to obtain feedback on the usability of each module. The investigators will also conduct virtual focus group discussions to obtain open ended feedback on the application. This study will provide valuable feedback, which will be used to improve and adapt the VIRTUES platform.",[116,28,26,85,117],"Heart Diseases","Pathologic Processes",{"date":95,"type":40},{"date":120,"type":40},"2024-04-18",{"date":122,"type":22},"2028-09-30",{"name":124,"class":102},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's",{"id":126,"slug":127,"hasResults":12,"nctId":128,"briefTitle":129,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":134,"conditions":135,"keywords":144,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":155},"100453457","learn-learning-environment-for-artificial-intelligence-in-radiotherapy-new-technology-100453457","NCT05184790","LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New Technology","LEARN","Inclusion Criteria:\n\n* Will receive radiation therapy for brain, breast, head and neck, kidney, liver, pancreas, prostate, spine cancer treatment or cardiac arrhythmia treatment at a participating centre.\n* Will receive CT planning, and a cone beam CT scan for at least one fraction of radiation therapy.\n* Will receive intrafraction x-ray imaging for the liver, pancreas, prostate, spine cancer treatment or cardiac arrhythmia treatment. As intrafraction imaging is not common standard of care for brain, breast, head and neck and kidney cancer treatments there is no requirement to have intrafraction x-ray imaging data for these anatomical sites.\n* Provides written informed consent.\n\nExclusion Criteria:\n\n* Less than 18 years of age",{"count":133,"type":22},300,"This study will develop a whole-of-body markerless tracking method for measuring the motion of the tumour and surrounding organs during radiation therapy to enable real-time image guidance.\n\nRoutinely acquired patient data will be used to improve the training, testing and accuracy of a whole-of-body markerless tracking method. When the markerless tracking method is sufficiently advanced, according to the PI of each of the data collection sites, the markerless tracking method will be run in parallel to, but not intervening with, patient treatments during data acquisition.",[28,136,137,138,139,140,141,142,143],"Breast Cancer","Prostatic Cancer","Brain Cancer","Kidney Cancer","Head and Neck Cancer","Liver Cancer","Pancreatic Cancer","Spinal Neoplasm",[145,146],"Radiation Therapy","markerless tracking","2026-05-18",{"date":93,"type":40},{"date":150,"type":40},"2023-02-28",{"date":152,"type":22},"2028-01-31",{"name":154,"class":102},"University of Sydney",4,{"id":157,"slug":158,"hasResults":12,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":80,"phases":165,"briefSummary":166,"conditions":167,"keywords":168,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":155},"100517615","the-magic-cardiac-ablation-european-study-100517615","NCT06019845","The MAGiC™ Cardiac Ablation European Study","The MAGiC™ Cardiac Ablation Feasibility Study \u002F Pomt Market Clinical Follow-Up","MAGiC-FESTPMCF","Inclusion Criteria:\n\n* Adult (aged 18 or older at time of consent);\n* Eligible for ablation procedures of an atrial or ventricular arrhythmia per European Heart Rhythm Association (EHRA) guidelines, lctrocardiographically documented within 12 months \\[rior to enrollment;\n* Able to be safely exposed to magnetic fields;\n* Willing and capable to attend scheduled follow up visits at the study site for the study duration (up to 12 months)\n* Willing and able to provide informed consent.\n\nExclusion Criteria:\n\n* Unable to be safely exposed to magnetic fields due to Magnetic Resonance Imaging Unsafe device (implanted device or device that cannot be safely removed for the procedure)\n* Unable to remain comfortable or hemodynamically stable in the supine position for an extended period of time\n* Weight exceeding 200 kg (the weight limit of the table)\n* Women of childbearing age who are pregnant or who plan to become pregnant within the course of their participation in the study. Must have a negative pregnancy test.\n* Presence of intracardiac thrombus within 12 weeks prior to enrollment\n* Where MAGiC would need to cross a prosthetic valve\n* Use of MAGiC in the coronary arteries\n* A history of sensitivity to foreign objects or extreme allergies\n* Acute illness or active systemic infection\n* Histological or anatomical abnormalities that may lead to post-operative complications including diminished resistance to infection\n* Unable to receive heparin or an acceptable alternative to achieve adequate anticoagulation\n* Acute myocardial infarct (within the previous 6 weeks)\n* Recent cardiac surgery (within the previous 8 weeks)\n* Unstable angina at the time of enrollment\n* History of embolism (cerebrovascular accident, transient ischemic attack, systemic embolism) in the previous 30 days\n* Previous cardiac ablation within the previous 30 days\n* EP ablation within the previous 6 weeks.\n* Life expectancy \\\u003C12 months per the physician opinion.\n* Currently or in the 30 days prior to consent, participation in an interventional clinical trial\n* Significant uncontrolled or unstable medical problems which, in the opinion of the Investigator, would preclude enrollment in and completion of the study (limitation on survival).\n* Any reason or condition that, in the judgement of the investigator, makes the patient ineligible for the investigation.",{"count":21,"type":22},[82],"The purpose of the first phase of this feasibility study is to gather safety and performance data on MAGiC to support European marketing approval.\n\nThe purpose of MAGiC-FEST PMCF Study is to collect safety and performance data with MAGiC to meet ongoing regulatory obligations.",[28],[26,169,170,171,172,173],"Atrial Flutter","Ventricular Tachycardia","Supraventricular Tachycardia","Ablation","Premature Ventricular Contractions","2026-04-28",{"date":176,"type":40},"2026-05-04",{"date":178,"type":40},"2024-01-02",{"date":180,"type":22},"2028-12-31",{"name":182,"class":46},"Stereotaxis",{"id":184,"slug":185,"hasResults":12,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":80,"phases":193,"briefSummary":194,"conditions":195,"keywords":198,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":213},"100457650","ablation-of-consecutive-atrial-tachycardia-100457650","NCT05239364","Ablation of Consecutive Atrial Tachycardia","Ablation of CONseCutive atriaL Tachycardia gUided by Ultra-high-DEnsity Mapping","CONCLUDE","Inclusion Criteria:\n\n* Consecutive AT subsequent to prior AF ablation procedure or cardiac surgery\n* Surface ECG-documentation of AT as primary clinical arrhythmia\n* ECG indicating stable, map-able AT (stable activation sequence, and CL stability) with cycle length ≥ 200ms\n\nExclusion Criteria:\n\n* \\\u003C 18 years\n* No previous atrial fibrillation ablation procedure or cardiac surgery\n* Pregnant women or women of childbearing potential without a negative pregnancy test within 48 hours prior to treatment\n* History of hemorrhagic diathesis or other coagulopathies\n* Contraindications for oral anticoagulation\n* Hyper- or hypothyroidism\n* Has any condition that would make participation not be in the best interest of the subject",{"count":192,"type":22},100,[82],"Ablation of consecutive atrial tachycardia (AT) after ablation of atrial fibrillation (AF) or cardiac surgery can be challenging due to complex substrate and AT mechanisms. A substantial portion of patients is known to show various tachycardias and recurrences occur in a noticeable number of cases. With the availability of novel ultra-high-density mapping techniques characterization and understanding of AT mechanisms and underlying substrate can be improved. Aim of this prospective, multi-center, randomized study is to compare a standard AT ablation approach versus minimalized ablation of the clinical AT in regards to arrhythmia free survival.",[196,116,28,197],"Heart Arrhythmia","Atrial Tachycardia",[199,200,201,202,203],"Atrial fibrillation","Atrial tachycardia","Pulmonary vein isolation","Electroanatomical mapping","High density mapping","2026-04-27",{"date":206,"type":40},"2026-04-30",{"date":208,"type":40},"2020-12-22",{"date":210,"type":22},"2027-06",{"name":212,"class":102},"Evangelical Hospital Düsseldorf",6,{"id":215,"slug":216,"hasResults":12,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":221,"targetDuration":4,"studyType":80,"phases":223,"briefSummary":224,"conditions":225,"keywords":226,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":103},"100543632","to-compare-and-evaluate-the-efficacy-and-safety-between-ts-rf-system-and-brk-transseptal-needles-used-for-transseptal-puncture-for-left-atrial-access-100543632","NCT06358391","To Compare and Evaluate the Efficacy and Safety Between TS-RF System and BRK Transseptal Needles Used for Transseptal Puncture for Left Atrial Access.","A Prospective, Multi-center, Randomized, Single-blind, Non-inferiority Confirmatory Study Designed to Compare and Assess Efficacy and Safety Between \"TS-RF System Consisting of a Electrosurgical System, General-purpose (TS-RF Generator) and a Electrosurgical System Electrode, Hand-controlled, General-purpose, Single-use (TS-RF Needle)\" and \"Needle, Puncture, Single-use (BRK Transseptal Needle)\", Both of Which Are Used for the Transseptal Puncture Performed to Enable Left Atrial Access for the Treatment of Symptomatic Arrhythmia and Mitral Stenosis","Inclusion Criteria:\n\n1. ≥ 18 years of age\n2. Diagnosed with one of the following cardiac disorders as shown in the medical record:\n\n   \\[Symptomatic arrhythmia\\]\n   * \"Atrial fibrillation\" diagnostics (including paroxysmal, persistent, long-standing persistent and permanent atrial fibrillation)\n\n     * Diagnostic criteria: atrial fibrillation lasting ≥ 30 seconds as a result of standard 12-lead electrocardiogram (ECG) or single-lead ECG\n     * ECG feature: irregular R-R interval, lack of visible P waves, irregular atrial activation\n     * Symptoms: fatigue, palpitation, dyspnea, chest discomfort, sleep disorders, mental stress\n     * Type:\n\n       * Paroxysmal atrial fibrillation (stopping within 48 hours without any treatment; restoring the sinus rhythm with cardioversion within 7 days)\n       * Persistent atrial fibrillation (persisting for ≥ 7 days; including sinus rhythm restoration with direct-current cardioversion (DCC) or pharmacological cardioversion after the persistence)\n       * Long-standing persistent atrial fibrillation (persisting for ≥ 1 year; including cases requiring cardioversion)\n       * Permanent atrial fibrillation (The patient and healthcare provider accept atrial fibrillation and do not consider cardioversion; if cardioversion is considered, the atrial fibrillation is reclassified as long-standing persistent atrial fibrillation)\n   * \"Paroxysmal Supraventricular Tachycardia\" diagnostics\n\n     = Clinical feature: The heart beats regularly 150 to 200 times per minute; the start and end of paroxysmal supraventricular tachycardia are clearly recognizable; these occur unexpectedly and stop abruptly.\n   * \"Ectopic Atrial Rhythm Tachycardia\" diagnostics\n\n     = Clinical feature: Heart rhythm of less than 250 beats per minute; morphologic difference from P waves in the sinus rhythm; P waves that precede QRS waves are identifiable.\n   * \"Ventricular Tachycardia\" diagnostics = Clinical feature: Wide QRS waves appear in succession with a rapid ventricular rate of ≥ 100 beats per minute; the patients is diagnosed with persistent ventricular tachycardia if tachycardia persists for ≥ 30 seconds but with non-persistent ventricular tachycardia if not applicable.\n   * \"Arrhythmia requiring left atrial access, including left atrial appendage occlusion, in the left atrium\" diagnostics = Clinical feature: moderate or higher risk of stroke, risk of bleeding, or contraindication to anticoagulation therapy\n\n   \\[Symptomatic mitral stenosis\\]\n\n   -\"Mitral Stenosis requiring percutaneous mitral valvuloplasty through left atrial access\" diagnostics\n   * Diagnostic criteria: confirmation of mitral stenosis with echocardiography and assessment of severity\n   * Symptoms: dyspnea; shortness of breath even at rest or inability to sleep in a supine position if dyspnea worsens; may accompanied by coughing, sputum, and chest pain.\n3. Understood this clinical study and voluntarily signed the informed consent form (ICF)1\n\nExclusion Criteria:\n\n\\[For symptomatic arrhythmia and mitral stenosis\\] If any of the following applies, you cannot participate in this clinical trial.1,26,37,45,46\n\n1. Patients with significant congenital heart defects, such as atrial septal defect or pulmonary vein (PV) abnormalities (excluding patent foramen ovale (PFO)).\n2. Thrombus in the left atrium\n3. Atrial fibrillation to reversible causes (e.g. hyperthyroidism, thoracic surgery)\n4. Known or suspected left atrial myxoma.\n5. Unstable angina.\n6. Pre-existing hemidiaphragmatic paralysis\n7. Contraindication to anticoagulation or radiocontrast materials\n8. liver disease (including active hepatitis) and kidney disease.\n9. Cerebral ischemic event (strokes or TIAs) during the six-month interval preceding the consent date\n10. Malignant tumors or hematological diseases or life expectancy of less than one (1) year.\n11. Currently participating or anticipated to participate in any other clinical trial of a drug, device or biologic that has the potential to interfere with the results of this study\n12. Unwilling or unable to comply fully with study procedures and follow-up\n13. A pregnant woman, a woman planning on becoming pregnant, or a lactating woman.\n14. Ineligible for study participation in the judgment of the investigator.",{"count":222,"type":22},70,[82],"The purpose of this study is to compare and assess efficacy and safety between the study device \"TS-RF system consisting of a electrosurgical system, general-purpose (TS-RF Generator) and a electrosurgical system electrode, hand-controlled, general-purpose, single-use (TS-RF Needle)\" and the control device \"needle, puncture, single-use (BRK Transseptal needle)\", both of which are used for the transseptal puncture performed to enable left atrial access for the treatment of symptomatic arrhythmia and mitral stenosis and then to demonstrate that the study device is non-inferior to the control device.",[28,26,116],[227,228,229,230],"Transseptal puncture","Left atrial access","Transseptal catheterization","Radiofrequency","2026-04-21",{"date":233,"type":40},"2026-04-24",{"date":235,"type":40},"2024-08-21",{"date":237,"type":22},"2026-10-31",{"name":239,"class":46},"Starmed",{"id":241,"slug":242,"hasResults":12,"nctId":243,"briefTitle":244,"officialTitle":244,"acronym":245,"eligibilityCriteria":246,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":247,"targetDuration":4,"studyType":80,"phases":249,"briefSummary":250,"conditions":251,"keywords":254,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":103},"100543828","radiotherapy-vs-catheter-ablation-for-ventricular-tachycardia-in-structural-heart-disease-100543828","NCT06360939","Radiotherapy vs Catheter Ablation for Ventricular Tachycardia in Structural Heart Disease","RadioAblate-VT","Inclusion Criteria:\n\n1. Structural heart disease (including ischaemic cardiomyopathy , non-ischaemic cardiomyopathy or congenital heart disease and defined as any one of\n\n   1. segmental or global decreased ventricular wall motion as defined by TTE, CT or cMRI\n   2. myocardial hypertrophy\n   3. myocardial scar (evidenced by late gadolinium enhancement on cMRI, wall thinning on cardiac CT, low voltage on electrophysiological study or abnormal intracardiac echocardiography)\n2. Recurrent monomorphic VT which can include\n\n   1. at least one episode of VT treated by ICD and\u002For\n   2. sustained VT (lasting \\>30s) and\u002For\n   3. inducible sustained VT on invasive electrophysiological study (EPS) or non-invasive programmed stimulation (NIPS)\n3. PAINESD score of ≥9 points and\u002For at least moderate risk of VT recurrence or death as defined by the I-VT score. Both are validated tools used clinically to identify patient at high risk of VT recurrence and\u002For mortality after CA.\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 years\n2. Life expectancy \\\u003C 3 months\n3. Catheter ablation deemed futile or with prohibitive risk by cardiac electrophysiologist.\n4. Unwilling or unable to provide consent\n5. Known cardiac channelopathies (e.g. Catecholaminergic polymorphic ventricular tachycardia (CPVT), long- or short QT syndrome, Brugada syndrome)\n6. Contraindications to radiotherapy as deemed by referring physician and\u002For radiation oncologist\n7. Pregnancy or breast feeding",{"count":248,"type":22},60,[82],"The goal of this randomized clinical trial is to test the efficacy of stereotactic body radiation therapy (SBRT) in treating ventricular tachycardia (VT) in patients with advanced structural heart disease. The main questions it aims to answer are:\n\n* What is the efficacy of SBRT compared to catheter ablation (CA) in achieving a ≥ 75% reduction in VT burden at 6 months\n* What is the comparable safety profile of SBRT vs CA Researchers will compare SBRT and CA (standard of care).",[170,252,28,253],"Cardiomyopathies","Ventricular Arrythmia",[255,256,257,258],"catheter ablation","stereotactic body radiation therapy","non invasive","radioablation","2026-02-15",{"date":261,"type":40},"2026-02-18",{"date":263,"type":40},"2025-11-03",{"date":265,"type":22},"2027-12-20",{"name":267,"class":102},"Western Sydney Local Health District",{"id":269,"slug":270,"hasResults":12,"nctId":271,"briefTitle":272,"officialTitle":272,"acronym":4,"eligibilityCriteria":273,"healthyVolunteers":12,"sex":18,"minAge":274,"maxAge":275,"enrollmentInfo":276,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":278,"conditions":279,"keywords":280,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":103},"100467407","the-dynamics-of-human-atrial-fibrillation-100467407","NCT05366361","The Dynamics of Human Atrial Fibrillation","Inclusion Criteria:\n\n* referred for ablation or Maze surgery at Stanford Medicine for persistent AF (i.e. which requires cardioversion to terminate and\u002For lasts \\>7 days)\n* Per our clinical practice and guidelines (Calkins et al., Heart Rhythm 2018), patients will have failed or be intolerant of \\>or= 1 anti-arrhythmic drug. Patients after Maze surgery typically have failed prior endocardial ablation.\n\nExclusion Criteria:\n\n* active coronary ischemia or decompensated heart failure\n* atrial or ventricular clot on trans-esophageal echocardiography\n* pregnancy (to minimize fluoroscopic exposure)\n* inability or unwillingness to provide informed consent\n* rheumatic valve disease (results in a unique AF phenotype)\n* thrombotic disease or venous filters\n* prior chest surgery is a relative contraindication for Maze surgery","22 Years","80 Years",{"count":277,"type":22},200,"Atrial fibrillation (AF) is an enormous public health problem in the United States, affecting 2-5 million Americans and causing rapid heart beats, stroke, heart failure or death. In this project, the applicant will develop a novel framework to better understand human AF that builds on agreement between several concepts for the disease. The applicant will develop strategies to identify AF patients who will best respond to each of several therapies, to guide personalized therapy.",[26,28],[281,282,283],"ablation","arrhythmias, cardiac","atrial fibrillation","2026-02-12",{"date":286,"type":40},"2026-02-17",{"date":288,"type":40},"2020-08-18",{"date":290,"type":22},"2027-12-30",{"name":292,"class":102},"Stanford University",{"id":294,"slug":295,"hasResults":12,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":299,"eligibilityCriteria":300,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":301,"targetDuration":303,"studyType":23,"phases":4,"briefSummary":304,"conditions":305,"keywords":317,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":103},"100589453","cardiac-assessment-for-recurrent-stroke-risk-evaluation-in-atrial-fibrillation-100589453","NCT06954610","Cardiac Assessment for Recurrent Stroke Risk Evaluation in Atrial Fibrillation","CARE-AF: Cardiac Assessment for Recurrent Stroke Risk Evaluation in Atrial Fibrillation","CARE-AF","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Written informed consent (by patient, next of kin or legally authorised representative)\n* Permanent, persistent, or paroxysmal AF previously known or diagnosed during the index hospitalisation\n* Acute (≤7 days), symptomatic ischemic stroke\n\nExclusion Criteria:\n\n* Life expectancy \\\u003C1 year according to the opinion of the investigator\n* Patient is unlikely to attend follow-up visits",{"count":302,"type":22},500,"12 Months","Background\n\nAtrial fibrillation (AF) is the most common cardiac arrhythmia, affecting up to 10% of the elderly. Ischemic stroke is the main complication of AF and cardioembolism is one of the leading causes of ischemic stroke, accounting for approximately one third of cases. Oral anticoagulant therapy (OAC) is a cornerstone in stroke prevention in patients with AF. According to randomized controlled trials of direct oral anticoagulants, a residual risk of ischemic stroke of 1-2% per year for so-called \"breakthrough stroke\" remains, despite adequate intake of OAC. The majority (\\>70%) of these breakthrough strokes are cardioembolic in nature and only a minority are related to medication issues (e.g. non-compliance) or other, non-AF related etiologies. Stroke recurrence risk after such a breakthrough stroke markedly increases to 8-9% per year indicating a particularly high-risk situation. Why OAC fails in certain patients, but not in others remains as poorly understood, as does the reason why the subsequent risk of stroke is so high.\n\nCurrent risk stratification tools, such as the widely used CHA2DS2-VA(Sc)-score, fail to predict stroke risk in such a high-risk cohort, as they were intended to guide the initiation of OAC in low to moderate risk patients. In light of new therapeutic strategies currently being investigated, such as percutaneous left atrial appendage occlusion in patients with breakthrough strokes (ELAPSE - NCT05976685) or in AF-patients deemed high-risk (LAAOS IV - NCT05963698), improved risk stratification and characterization of high-risk AF patients is highly warranted.\n\nSeveral clinical factors, such as those reflected in the CHA2DS2-VA(Sc)-score, and especially a high AF-burden are associated with increased risk of cardioembolic stroke. Several cardiac serum biomarkers are thought to be surrogates not only of cardiac function, but also of cardioembolic risk. Reflecting ventricular and atrial wall tension, myocardial injury, oxidative stress and thrombogenicity, elevated NT-proBNP, MR-proANP, high-sensitive Troponin T and D-Dimers have all been associated with cardioembolic stroke in different AF and non-AF populations. As the main location of thrombus formation, the left atrium (LA) and more specifically its appendage (LAA) are of particular interest in the pathogenesis of cardioembolism. Pronounced LA-enlargement, compared to a normal-sized LA, correlates with an increased risk of cardioembolism in AF-patients. As over 80% of thrombi form within the LAA, several LAA-characteristics, such as slower LAA-flow velocity and larger LAA-orifice area have also been demonstrated to be associated with higher stroke risk. Although there is data on each one of these factors, they have only been investigated in low to moderate risk populations, such as AF-patients without prior stroke, OAC-naïve patients, or even within the general population as a whole. Their role in high-risk AF-patients and in breakthrough stroke is unknown.\n\nHypothesis\n\nThe investigators hypothesize that specific clinical factors, serum cardiac biomarkers and markers of LA- and LAA-morphology and function are associated with breakthrough stroke \u002F OAC-failure and may improve risk stratification.\n\nMethods\n\nCARE-AF is a single-center, prospective cohort study conducted at the Stroke Center of the Inselspital, University Hospital Bern, Switzerland. Patients with an index ischemic stroke and AF (breakthrough and non-breakthrough cases) will be enrolled. The investigators will collect clinical data, serum cardiac biomarkers and echocardiographic indices of the LA and LAA. All patients will receive standardized annual follow-ups until the end of the study, defined as 12 months after the inclusion of the last participant. The primary endpoint is ischemic stroke or systemic embolism during follow-up. First, in a cross-sectional design, the study will assess the association between serum cardiac biomarkers and echocardiographic indices among patients with breakthrough vs. non-breakthrough stroke as index event, applying multivariate regression models. Second, the investigators will perform a longitudinal analysis assessing the association between the variables mentioned above and breakthrough stroke as index event with the primary endpoint, using multivariate Cox regression models. The study aims to enroll a minimum of 500 patients, which provides sufficient power to detect a clinically meaningful adjusted hazard ratio for recurrent stroke of 1.5 with 80% power at an alpha level of 5%.\n\nConclusion\n\nThe results of this project will enhance understanding of the role of specific clinical factors, cardiac serum biomarkers and echocardiographic indices in the residual risk of stroke in patients with AF on anticoagulation therapy. They may improve current risk stratification and have the potential to help guide therapeutic decisions in high-risk situations considering evolving therapeutic possibilities.",[306,26,307,308,309,310,28,116,311,312,313,314,315,316],"Ischemic Stroke","Cerebrovascular Disorders","Brain Diseases","Central Nervous System Diseases","Vascular Diseases","Brain Infarction","Brain Ischemia","Infarction Cerebral","Stroke","Cardioembolic Stroke","Ischemia",[318,319,320,321,322,199,323,324],"Ischemic stroke","Direct oral anticoagulation","Anticoagulation","Breakthrough stroke","Risk stratification","Anticoagulant therapy","Direct oral anticoagulant","2025-11-17",{"date":327,"type":40},"2025-11-20",{"date":329,"type":40},"2025-11-04",{"date":331,"type":22},"2028-06-30",{"name":333,"class":102},"Insel Gruppe AG, University Hospital Bern",{"id":335,"slug":336,"hasResults":12,"nctId":337,"briefTitle":338,"officialTitle":338,"acronym":4,"eligibilityCriteria":339,"healthyVolunteers":12,"sex":18,"minAge":274,"maxAge":275,"enrollmentInfo":340,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":341,"conditions":342,"keywords":343,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":352,"locationsCount":103},"100467794","machine-learning-in-atrial-fibrillation-100467794","NCT05371405","Machine Learning in Atrial Fibrillation","Inclusion Criteria:\n\n* undergoing ablation at Stanford of (a) paroxysmal AF (self-terminates \\\u003C 7 days), or (b) persistent AF (requires cardioversion to terminate).\n* Per our clinical practice and guidelines (Calkins et al, Heart Rhythm 2012), patients will have failed or be intolerant of ≥ 1 anti-arrhythmic drug.\n\nExclusion Criteria:\n\n* active coronary ischemia or decompensated heart failure\n* atrial or ventricular clot on trans-esophageal echocardiography\n* pregnancy (to minimize fluoroscopic exposure)\n* inability or unwillingness to provide informed consent\n* rheumatic valve disease (results in a unique AF phenotype)\n* thrombotic disease or venous filters",{"count":79,"type":22},"Atrial fibrillation is a serious public health issue that affects over 5 million Americans (Miyazaka, Circulation 2006) in whom it may cause skipped beats, dizziness, stroke and even death. Therapy for AF is currently suboptimal, in part because AF represents several disease states of which few have been delineated or used to successfully guide management. This study seeks to clarify this delineation of AF types using machine learning (ML).",[26,28],[344,281,283],"machine learning","2025-11-12",{"date":347,"type":40},"2025-11-14",{"date":349,"type":40},"2020-02-12",{"date":351,"type":22},"2027-12",{"name":292,"class":102},{"id":354,"slug":355,"hasResults":12,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":4,"eligibilityCriteria":359,"healthyVolunteers":360,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":361,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":362,"conditions":363,"keywords":364,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":379,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":385,"locationsCount":103},"100127050","biospecimen-repository-for-cardiac-arrhythmias-at-the-cleveland-clinic-100127050","NCT00921986","Biospecimen Repository for Cardiac Arrhythmias at the Cleveland Clinic","Cleveland Clinic Arrhythmia Biospecimen Repository (Cleveland Clinic Arrhythmia BioBank)","Inclusion Criteria:\n\n* Male or female at least 18 years old\n* Subjects with a history of or current cardiac arrhythmia, family members of subjects with cardiac arrhythmias, or no cardiac arrhythmia if a Control Subject.\n\nExclusion Criteria:\n\n* Subjects previously enrolled in the Arrhythmia BioBank",true,{"count":113,"type":22},"Biorepository of blood and or tissue samples from patients presenting with cardiac arrhythmia syndromes.",[28],[365,366,367,283,368,369,370,371,372,373,374,375,376,377],"genetics","biorepository","cardiac death","ventricular fibrillation","ventricular tachycardia","supraventricular tachycardias","premature ventricular complexes","premature atrial complexes","atrioventricular and intraventricular blocks","sinus node dysfunction","syncope","vasovagal reactivity","postural orthostatic tachycardia syndrome","2025-09-08",{"date":380,"type":40},"2025-09-10",{"date":382,"type":40},"2009-03",{"date":384,"type":22},"2035-12",{"name":386,"class":102},"The Cleveland Clinic",{"id":388,"slug":389,"hasResults":12,"nctId":390,"briefTitle":391,"officialTitle":391,"acronym":392,"eligibilityCriteria":393,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":394,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":395,"conditions":396,"keywords":398,"overallStatus":404,"whyStopped":4,"lastUpdateSubmitDate":405,"lastUpdatePostDateStruct":406,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":412,"locationsCount":4},"100559429","wearable-cardiac-monitor-to-enhance-detection-of-arrhythmia-recurrence-after-catheter-ablation-of-atrial-fibrillation-100559429","NCT06564012","Wearable Cardiac Monitor to Enhance Detection of Arrhythmia Recurrence After Catheter Ablation of Atrial Fibrillation","WEAR-AF","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Diagnosed with paroxysmal or persistent atrial fibrillation.\n* Scheduled to undergo catheter ablation for atrial fibrillation.\n* Able to provide informed consent.\n* Willing to wear the Skiin garments (chest band or bralette) for the duration of the study (approximately 1 month pre and 6 months post-ablation).\n* Have a smartphone with an Operating System compatible with the Skiin Connected Life App (Android 9+ or iOS 13+)\n\nExclusion Criteria:\n\n* Adverse reaction to Skiin garments (e.g. skin allergy)\n\nThe relevant Skiin Underwear contraindications acting as exclusion criteria for this study are:\n\n* Pacemaker and\u002For (ICD) implantable cardioverter defibrillator users.\n* Pregnancy",{"count":192,"type":22},"The WEAR-AF study is a prospective, multicenter clinical trial designed to evaluate the efficacy of wearable technology in the detection, monitoring, and management of atrial fibrillation (AF). This study aims to assess how wearable devices, such as smartwatches equipped with electrocardiogram (ECG) capabilities, can be used to identify AF episodes, guide treatment decisions, and ultimately improve patient outcomes.\n\nParticipants will be individuals diagnosed with or at high risk for atrial fibrillation. The study will track the accuracy of AF detection, patient adherence to monitoring, and the impact on clinical outcomes, including stroke prevention, symptom management, and quality of life.\n\nThe findings from WEAR-AF are expected to contribute to the growing body of evidence supporting the integration of wearable technology into routine clinical practice for AF management, offering insights into its potential to enhance patient care and reduce healthcare costs.",[26,28,116,85,397],"Stroke Prevention",[399,400,401,402,403],"digital health","wearable technology","electrocardiography","remote monitoring","patient adherence","NOT_YET_RECRUITING","2025-05-20",{"date":407,"type":40},"2025-05-25",{"date":409,"type":22},"2025-07-01",{"date":411,"type":22},"2026-12",{"name":413,"class":102},"Sunnybrook Health Sciences Centre",{"id":415,"slug":416,"hasResults":12,"nctId":417,"briefTitle":418,"officialTitle":419,"acronym":4,"eligibilityCriteria":420,"healthyVolunteers":360,"sex":18,"minAge":19,"maxAge":275,"enrollmentInfo":421,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":423,"conditions":424,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":103},"100585750","mechanisms-of-brain-heart-injury-of-post-intracranial-hemorrhage-100585750","NCT06906432","Mechanisms of Brain-Heart Injury of Post-Intracranial Hemorrhage","Multimodal Omics and Imaging Study on the Mechanisms of Brain-heart Injury in Patients With Intracranial Hemorrhage","Inclusion Criteria:\n\n1. Patients aged 18 years or older at the time of enrollment.\n2. Acute intracranial hemorrhage confirmed by neuroimaging (CT, MRI，CTA, MRA, or DSA) within 48 hours of symptom onset.\n3. Ability to provide informed consent or have a legally authorized representative willing to consent on their behalf.\n\nExclusion Criteria:\n\n1. Patients who refuse to participate in the study or cannot provide informed consent.\n2. Patients with a history of significant cardiovascular disease, including myocardial infarction, heart failure, or arrhythmias, unless stable and well-controlled.\n3. Patients who have undergone cardiac bypass surgery, stent placement, or other cardiovascular interventions within the past 6 months.\n4. Patients with active brain tumors, ischemic stroke within 3 months or a history of previous brain injury that could confound the study findings.\n5. Patients with active malignant disease, severe inflammatory or infectious disease, or those who have undergone surgery for any reason within the past 3 months.\n6. Patients with any condition that, in the opinion of the investigator, would make it unsafe or impractical to participate in the study.",{"count":422,"type":22},1000,"Intracranial hemorrhage is a condition characterized by high mortality rates and suboptimal functional outcomes. It precipitates both direct brain injury and subsequent secondary injuries, including delayed cerebral ischemia, brain edema, and hydrocephalus. Complications such as cardiac injury may also arise, categorizing them within the cerebrocardiac syndrome (CCS). The clinical spectrum of CCS encompasses acute myocardial injury, acute coronary syndrome, left ventricular systolic and diastolic dysfunction, cardiac arrhythmias, and sudden cardiac death, all of which are associated with increased mortality and deterioration in patient status. The precise pathophysiological mechanisms underlying both cerebral and cardiac injuries remain enigmatic, and the implications for diagnosis and therapeutic strategies are yet to be fully explored.\n\nIn this study, we propose to enroll patients with intracranial hemorrhage who will undergo conventional treatment and comprehensive multidisciplinary evaluations. Our observational research is grounded in a multimodal omics and imaging approach, aimed at investigating both local and systemic injuries subsequent to intracranial hemorrhage. This comprehensive strategy is intended to facilitate precise diagnosis, risk stratification, and clinical decision-making, while also shedding light on the pathophysiological mechanisms involved.\n\nThe primary objectives of this research are to address the following key questions:\n\n* \\[Question 1\\] What are the pathophysiological mechanisms underlying cardiac injury in patients with intracranial hemorrhage?\n* \\[Question 2\\] What are the pathophysiological mechanisms responsible for early and delayed brain injuries following intracranial hemorrhage?\\"",[425,426,427,428,26,429,430,28,431,432,433,434],"Subarachnoid Hemorrhage, Aneurysmal","Cerebrocardiac Syndrome","Mass Spectrometry","Heart Failure","Ischemic Heart Disease","Heart Infarction","Delayed Cerebral Ischemia","Hydrocephalus","Vasospasm, Cerebral","Intracerebral Hemorrhage","2025-03-29",{"date":437,"type":40},"2025-04-02",{"date":439,"type":40},"2024-08-01",{"date":441,"type":22},"2036-12-01",{"name":443,"class":102},"Beijing Tiantan Hospital",{"id":445,"slug":446,"hasResults":12,"nctId":447,"briefTitle":448,"officialTitle":449,"acronym":450,"eligibilityCriteria":451,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":452,"targetDuration":4,"studyType":80,"phases":454,"briefSummary":455,"conditions":456,"keywords":457,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":464,"startDateStruct":465,"completionDateStruct":467,"leadSponsor":469,"locationsCount":103},"100537020","relevance-of-recording-an-ecg-trace-with-a-connected-watch-100537020","NCT06272396","Relevance of Recording an ECG Trace With a Connected Watch","Feasibility and Diagnostic Relevance of Recording an ECG Trace With a Connected Watch","ECG-MC","Inclusion Criteria:\n\n* Patients hospitalized or seen in consultation in one of the departments of the Haut Lévêque cardiology hospital,\n* Patient of both sexes, minor (from birth to 18 years) or adult,\n* Free, informed and written consent from the patient or, in the case of minors, from the legal parent (at the latest on the day of inclusion and before any examination required for the research),\n* Subject affiliated to or benefiting from a social security regime.\n\nExclusion Criteria:\n\n* Person incapable of giving consent,\n* Person subject to a legal protection measure (safeguard of justice, tutorship or curatorship),\n* A person deprived of liberty by judicial or administrative decision.",{"count":453,"type":22},3000,[82],"Over the past few years, various systems have been developed to record ECG traces on an ambulatory basis. The latest connected watch models feature 2-electrode ECG recording. This single (1D) or six derivations (6D) can be used to derive a wealth of information about the heart's rhythm. The information that can be derived from an ECG recording with a derivation goes far beyond̀ simple differentiation between atrial fibrillation and sinus rhythm. In contrast, in various clinical situations, a tracing restricted to an intracardiac defibrillator (ICD) may prove falsely normal, wrongly reassuring a patient and delaying management. The primary objective of the study is to evaluate the sensitivity of ECG-1D or 6D recordings from a connected watch in measuring electrical parameters, compared with a standard ECG-12D, also to obtain a bank of tracings, to create and validate an artificial intelligence algorithm for the automatic analysis of ECG tracings recorded with a connected watch and also to validate the feasibility and sensitivity of recording an ECG tracing with a connected watch in children.",[28],[458,459,460,461,462],"Electrocardiogram","Smart watch","Arrhythmia","Artificial Intelligent","Remote monitoring","2025-03-28",{"date":437,"type":40},{"date":466,"type":40},"2024-03-26",{"date":468,"type":22},"2028-03-26",{"name":470,"class":102},"University Hospital, Bordeaux",{"id":472,"slug":473,"hasResults":12,"nctId":474,"briefTitle":475,"officialTitle":476,"acronym":477,"eligibilityCriteria":478,"healthyVolunteers":360,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":479,"targetDuration":481,"studyType":23,"phases":4,"briefSummary":482,"conditions":483,"keywords":490,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":497,"lastUpdatePostDateStruct":498,"startDateStruct":500,"completionDateStruct":502,"leadSponsor":504,"locationsCount":103},"100479320","clinical-cohort-study---trust-100479320","NCT05521451","Clinical Cohort Study - TRUST","Longterm Outcome and Predictors for Recurrence After Medical and Interventional Treatment of Arrhythmias At the University Heart Center Hamburg","TRUST","Inclusion Criteria:\n\n* Cardiac arrhythmia, including congenital cardiac arrhythmia diagnosed at baseline or high risk for cardiac arrhythmia\n* Age ≥ 18 years\n* Written informed consent\n* Ability to provide written informed consent in accordance with Good Clinical Practice and local legislation\n\nExclusion Criteria:\n\n* Insufficient knowledge of the German language to understand study documents and interview without translation\n* Physical or psychological incapability to cooperate in the investigation",{"count":480,"type":22},5000,"10 Years","The \"Long-term Outcome and Predictors for Recurrence after Medical and Interventional Treatment of Arrhythmias at the University Heart Center Hamburg\" (TRUST) study is an investor-initiated, single-center, prospective clinical cohort study including patients treated with cardiac arrhythmias or at high risk for cardiac arrhythmias. The design enables prospective, low-threshold, near complete inclusion of patients with arrhythmias treated at the UHZ. Collection of routine follow-up data, detailed procedural information and systematic biobanking will enable precise and robust phenotyping.",[28,26,169,170,197,484,485,486,171,487,488,489],"Arrhythmogenic Right Ventricular Dysplasia","Long QT Syndrome","Brugada Syndrome","Catecholaminergic Polymorphic Ventricular Tachycardia","Torsades De Pointes","Atrial Cardiomyopathy",[491,492,493,494,495,496,489],"Catheter Ablation","Biomarkers","Cardiac Arrhythmia","eHealth","Digital Cardiology","Echocardiography","2025-03-25",{"date":499,"type":40},"2025-03-30",{"date":501,"type":40},"2021-03-17",{"date":503,"type":22},"2031-12-31",{"name":505,"class":102},"Universitätsklinikum Hamburg-Eppendorf",{"id":507,"slug":508,"hasResults":12,"nctId":509,"briefTitle":510,"officialTitle":511,"acronym":4,"eligibilityCriteria":512,"healthyVolunteers":12,"sex":18,"minAge":513,"maxAge":514,"enrollmentInfo":515,"targetDuration":4,"studyType":80,"phases":517,"briefSummary":518,"conditions":519,"keywords":523,"overallStatus":404,"whyStopped":4,"lastUpdateSubmitDate":525,"lastUpdatePostDateStruct":526,"startDateStruct":528,"completionDateStruct":530,"leadSponsor":532,"locationsCount":103},"100583057","low-and-moderete-flow-anaesthesia-on-haemodynamics-100583057","NCT06871371","Low and Moderete Flow Anaesthesia on Haemodynamics","The Comparison of the Effects of Low and Medium Flow Anesthesia on Haemodynamics, Arrhytmia Risk and Cerebral Oxygenation in Laparoscopic Cholecystomy Cases","Inclusion Criteria:\n\n* being ASA1-2 status\n* between the ages of 18-70\n* who are planned for laparoscopic cholecystectomy\n\nExclusion Criteria:\n\n* Patients who refuse to give informed consent\n* Pregnant and breastfeeding patients\n* Morbidly obese patients (Body mass index over 40)\n* Patients with uncontrolled diabetes mellitus, with serious cardiovascular, pulmonary, renal, hepatic disease, obstructive sleep apnea, with electrolyte imbalance- Those with a history of alcohol or drug abuse, with perioperative hemodynamic instability\n* Patients using drugs known to prolong myocardial repolarization\n* inability to increase SPO2 above 95 despite necessary intervention","17 Years","70 Years",{"count":516,"type":22},76,[82],"The study topic investigates the potential advantages of low-flow anesthesia in terms of physiological protection and resource saving.",[520,521,522],"Hemodynamics Instability","Arrhythmias Cardiac","Cerebral Oxygenation",[524],"Low-Medium Flow Anesthesia, Hemodynamics, Oxygenation","2025-03-06",{"date":527,"type":40},"2025-03-11",{"date":529,"type":22},"2025-03-15",{"date":531,"type":22},"2025-04-15",{"name":533,"class":534},"Umraniye Education and Research Hospital","OTHER_GOV",{"id":536,"slug":537,"hasResults":12,"nctId":538,"briefTitle":539,"officialTitle":540,"acronym":4,"eligibilityCriteria":541,"healthyVolunteers":12,"sex":18,"minAge":542,"maxAge":4,"enrollmentInfo":543,"targetDuration":4,"studyType":80,"phases":544,"briefSummary":545,"conditions":546,"keywords":550,"overallStatus":404,"whyStopped":4,"lastUpdateSubmitDate":557,"lastUpdatePostDateStruct":558,"startDateStruct":560,"completionDateStruct":562,"leadSponsor":563,"locationsCount":4},"100558048","analysis-of-the-efficacy-and-stability-of-a-wearable-ecg-monitor-100558048","NCT06546046","Analysis of the Efficacy and Stability of a Wearable ECG Monitor","Analysis of the Efficacy and Stability of a Single-Channel Patch-Type Wearable Electrocardiogram Monitor","Inclusion Criteria:\n\n1. Adults aged 19 years or older\n2. Patients admitted to Chonnam National University Hospital who require ECG monitoring\n3. Individuals who have expressed their intention to participate in this study or have obtained written consent from a proxy\n\nExclusion Criteria:\n\n1. Individuals who are unable to provide consent themselves or through a legally designated representative\n2. Individuals deemed unsuitable for participation in the clinical trial based on the researcher's judgment","19 Years",{"count":192,"type":22},[82],"This study aims to analyze the efficacy and safety of wearable electrocardiogram (ECG) monitoring by simultaneously attaching a single-channel patch-type wearable ECG monitoring device (HiCardi+ by Mezoo Co., Ltd.) and a telemetry device (IntelliVue MX40 by Philips) used in actual wards to patients prescribed with ECG monitoring",[28,547,548,26,169,549],"Bradycardia","Tachycardia","Ventricular Premature Complexes",[551,552,553,554,555,556],"Monitoring","Telemetry","Wearable device","Arrhythmia alarm","Signal loss","Satisfaction survey","2024-08-11",{"date":559,"type":40},"2024-08-14",{"date":561,"type":22},"2024-09-09",{"date":499,"type":22},{"name":564,"class":102},"Mezoo Co., Ltd.",{"id":566,"slug":567,"hasResults":12,"nctId":568,"briefTitle":569,"officialTitle":570,"acronym":571,"eligibilityCriteria":572,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":573,"targetDuration":481,"studyType":23,"phases":4,"briefSummary":575,"conditions":576,"keywords":578,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":586,"lastUpdatePostDateStruct":587,"startDateStruct":589,"completionDateStruct":591,"leadSponsor":593,"locationsCount":47},"100540000","multicenter-evaluation-of-patients-using-latitude-monitoring-system-100540000","NCT06311149","Multicenter Evaluation of Patients Using LATITUDE Monitoring System","Multicenter Evaluation of Patients Using LATITUDE Monitoring System: Multitude Study","Multitude","Inclusion Criteria:\n\n* Subject is willing and capable of providing informed consent to collect\u002Fstore\u002Fprocess personal health information by the sponsor or such consent is provided by a legally designated representative, if required by local law or regulation.\n* Subject is:\n\n  1. prospectively scheduled for receiving a device monitored through the LATITUDE monitoring system\n  2. retrospectively enrolled after having received a device monitored through the LATITUDE monitoring system\n\nExclusion Criteria:\n\n* Subject foreseen not to be followed at the enrolling center for at least 1 year after having received the device.\n* Subject is receiving a device that is not approved for commercial use at the time of procedure.",{"count":574,"type":22},20000,"The Multitude is a registry of patients who receive commercially available CIEDs that remotely communicate through the LATITUDE monitoring system and transfer data to a central database.\n\nThe registry is designed to constitute a shared environment for the collection, management, analysis and reporting of clinical and diagnostic data, adopted by a network of European scientifically-motivated physicians who use rhythm management diagnostic and therapeutic solutions from Boston Scientific in their clinical practice.\n\nThe Multitude study will facilitate the sharing of scientific proposals within a large network of researchers, and it will allow researchers to record the experience with medical devices throughout the device and patient lifecycle.",[85,28,428,577],"Sudden Cardiac Death",[579,580,581,582,583,584,462,585],"Cardiac implantable electrical device","Implantable cardioverter defibrillator","Pacemaker","Cardiac resynchronization therapy","Subcutaneous defibrillator","Implantable cardiac monitor","Latitude monitoring system","2024-08-08",{"date":588,"type":40},"2024-08-12",{"date":590,"type":40},"2023-12-01",{"date":592,"type":22},"2043-12-31",{"name":594,"class":102},"University Hospital of Ferrara",{"id":596,"slug":597,"hasResults":12,"nctId":598,"briefTitle":599,"officialTitle":600,"acronym":4,"eligibilityCriteria":601,"healthyVolunteers":12,"sex":18,"minAge":602,"maxAge":542,"enrollmentInfo":603,"targetDuration":4,"studyType":80,"phases":605,"briefSummary":606,"conditions":607,"keywords":608,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":616,"lastUpdatePostDateStruct":617,"startDateStruct":619,"completionDateStruct":621,"leadSponsor":623,"locationsCount":103},"100497366","validation-of-ecg-waveform-and-arrhythmia-diagnosis-concordance-for-pediatric-patients-using-ecg-monitoring-patch-100497366","NCT05756309","Validation of ECG Waveform and Arrhythmia Diagnosis Concordance for Pediatric Patients Using ECG Monitoring Patch","Validation of Electrocardiogram Waveform, Heart Rate Accuracy and Arrhythmia Diagnosis Concordance for Pediatric Patients Using Single-channel ECG Monitoring Patch and Holter Monitoring","Inclusion Criteria:\n\n* More than 29 days old and less than 19 years old\n* Patients who are need regular Holter electrocardiography among outpatients or hospitalized patients at the Pediatrics, Samsung Medical Center\n* Those who gave written consent to this clinical study or obtained the written consent of the legal representative\n\nExclusion Criteria:\n\n* Patients who cannot give consent through the patient ownself or legal representative\n* If the researcher judges that participation in this study is inappropriate for other reasons","29 Days",{"count":604,"type":22},105,[82],"This study will verify the 1-channel patch-type ECG's arrhythmia diagnostic concordance rate and electrocardiogram measurement performance in pediatric patients by collecting ECG signals from patch-type ECG and Holter device simultaneously for data analysis.",[28],[609,610,611,612,613,614,615],"ECG monitoring patch","Validation of Electrocardiogram waveform","Validation of heart rate accuracy","Validation of arrhythmia diagnosis concordance","Patients with cardiac arrhythmia","Holter","Wearable patch-type electrocardiograph","2024-08-06",{"date":618,"type":40},"2024-08-09",{"date":620,"type":40},"2023-01-16",{"date":622,"type":22},"2024-12-30",{"name":564,"class":102},{"id":625,"slug":626,"hasResults":12,"nctId":627,"briefTitle":628,"officialTitle":629,"acronym":4,"eligibilityCriteria":630,"healthyVolunteers":360,"sex":18,"minAge":19,"maxAge":275,"enrollmentInfo":631,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":633,"conditions":634,"keywords":635,"overallStatus":404,"whyStopped":4,"lastUpdateSubmitDate":637,"lastUpdatePostDateStruct":638,"startDateStruct":640,"completionDateStruct":642,"leadSponsor":644,"locationsCount":4},"100524022","risk-stratifications-for-patients-with-palpitations-100524022","NCT06103305","Risk Stratifications for Patients With Palpitations","Risk Stratifications for Patients Come With Palpitations in Assiut and Suez Canal University Hospitals","Inclusion Criteria:\n\nThe present study will be conducted on patients with Palpitations \"without intently selected certain gender\" and had 18 years old or more\n\nExclusion Criteria:\n\npatients refusing study will be excluded.",{"count":632,"type":22},208,"the aim of the study is to early diagnose and early proper mangment of those patients who have palpitations specially of cardiac origin",[28],[636],"palpitations","2024-07-29",{"date":639,"type":40},"2024-07-30",{"date":641,"type":22},"2024-10",{"date":643,"type":22},"2026-09",{"name":645,"class":102},"Assiut University",{"id":647,"slug":648,"hasResults":12,"nctId":649,"briefTitle":650,"officialTitle":651,"acronym":4,"eligibilityCriteria":652,"healthyVolunteers":360,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":653,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":654,"conditions":655,"keywords":4,"overallStatus":404,"whyStopped":4,"lastUpdateSubmitDate":656,"lastUpdatePostDateStruct":657,"startDateStruct":659,"completionDateStruct":661,"leadSponsor":663,"locationsCount":4},"100555557","12-lead-ecg-database-100555557","NCT06513637","12 Lead ECG Database","12-Lead ECG Database","Inclusion Criteria:\n\n* are 18 years of age or older.\n* are able to read, understand, and sign informed consent documentation.\n* are willing to undergo simultaneous recordings with the Sansa and 12-lead ECG device.\n\nExclusion Criteria:\n\n* exhibit deformities of the chest (e.g., pronounced scarring, pectus carinatum) that would interfere with sensor placement\n* have broken or injured skin that would interfere with sensor placement\n* are known to experience adverse reactions to medical-grade adhesive\n* are pregnant",{"count":21,"type":22},"The purpose of this investigation is to collect a database of simultaneous electrocardiogram (ECG) recordings from the SANSA device and a reference 12-lead ECG recording device.\n\nThe purpose of this database is to aid development and evaluation of algorithms to detect cardiac arrhythmias and other parameters from the electrocardiogram. Example analyses that may utilize this database are ECG vector transformations and ECG waveform timing analyses.\n\nThe study is for scientific purposes and does not intend to diagnose, cure, mitigate, treat, or prevent any disease and does not involve any medical procedures.",[28],"2024-07-16",{"date":658,"type":40},"2024-07-22",{"date":660,"type":22},"2024-07-19",{"date":662,"type":22},"2025-12-31",{"name":664,"class":46},"Huxley Medical, Inc.",{"id":666,"slug":667,"hasResults":12,"nctId":668,"briefTitle":669,"officialTitle":670,"acronym":671,"eligibilityCriteria":672,"healthyVolunteers":12,"sex":18,"minAge":673,"maxAge":275,"enrollmentInfo":674,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":676,"conditions":677,"keywords":688,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":693,"lastUpdatePostDateStruct":694,"startDateStruct":696,"completionDateStruct":698,"leadSponsor":699,"locationsCount":103},"100516173","prognosis-prediction-system-of-patients-with-cardiovascular-and-cerebrovascular-diseases-based-on-multi-omics-100516173","NCT06001073","Prognosis Prediction System of Patients With Cardiovascular and Cerebrovascular Diseases Based on Multi-omics","Prognosis Prediction System of Patients With Cardiovascular and Cerebrovascular Diseases Based on Multi-omics (PROSPECT): a National, Multicenter, Retrospective-prospective, Cohort Study","PROSPECT","Inclusion Criteria:\n\n* Patients who are regularly visited and followed up in the appropriate patient; department.\n* All patients met at least one of the following diagnostic criteria for cardiovascular and cerebrovascular diseases:\n* coronary artery disease group;\n* arrhythmia group;\n* heart valve disease group;\n* aortic dissection group;\n* cardiac masses group;\n* myocarditis group;\n* hypertension group;\n* cardiomyopathy group;\n* structural heart disease group;\n* ischemic cerebrovascular disease group;\n* hemorrhagic cerebrovascular disease group;\n* intracranial space occupying lesion group.\n\nExclusion Criteria:\n\n* Age \\\u003C3 years or \\>80 years old;\n* Pregnant and lactating women;\n* The patient declined to provide informed consent to participate in the study;\n* None of the above was met, but the patient was temporarily unable to sign the informed consent form due to coma and other reasons, and no legal representative signed it instead. Depending on the patient's condition, the patient may not be able to regain consciousness and sign the informed consent form.","3 Years",{"count":675,"type":22},25000,"The etiology and specific pathogenesis of many cardiovascular diseases such as coronary atherosclerosis, cardiomyopathy, atrial fibrillation, and stroke are still unclear. Improving diagnosis and treatment, clarifying the pathogenesis, and providing scientific basis for the prevention and treatment are hot research topics in the study of cardiovascular and cerebrovascular diseases. This study intends to collect clinical data and biological specimen data of patients with cardiovascular and cerebrovascular diseases who meet the inclusion and exclusion criteria, and use multi-omics technology to deeply understand the pathogenic mechanisms of cardiovascular and cerebrovascular diseases and provide new ideas for specific and individualized treatment of patients with cardiovascular and cerebrovascular diseases, to construct early predictive prognostic models and provide a basis for effective treatment of clinical practice in patients with cardiovascular and cerebrovascular diseases.",[678,28,679,680,681,682,683,252,684,685,686,687],"Coronary Artery Disease","Heart Valve Diseases","Aortic Dissection","Heart Neoplasms","Myocarditis","Hypertension","Structural Heart Disease","Ischemic Cerebrovascular Disease","Hemorrhagic Cerebrovascular Disease","Brain Neoplasms",[689,690,691,692],"Cardiovascular diseases","Cerebrovascular diseases","Prognosis","Multi-omics","2024-07-10",{"date":695,"type":40},"2024-07-12",{"date":697,"type":40},"2022-12-05",{"date":180,"type":22},{"name":700,"class":102},"First Affiliated Hospital Xi'an Jiaotong University",{"id":702,"slug":703,"hasResults":12,"nctId":704,"briefTitle":705,"officialTitle":706,"acronym":4,"eligibilityCriteria":707,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":708,"targetDuration":4,"studyType":80,"phases":710,"briefSummary":711,"conditions":712,"keywords":713,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":717,"lastUpdatePostDateStruct":718,"startDateStruct":720,"completionDateStruct":722,"leadSponsor":724,"locationsCount":726},"100551096","accuracy-of-laa-occluder-size-selection-ct-vs-dsa-during-combined-af-ablation-and-laa-occlusion-100551096","NCT06455644","Accuracy of LAA Occluder Size Selection: CT vs. DSA During Combined AF Ablation and LAA Occlusion","The Accuracy of Left Atrial Appendage Occluder Size Selection Between Preoperative CT and Intraoperative DSA Evaluation During a Combined Atrial Fibrillation Ablation and Left Atrial Appendage Occlusion Procedure","Inclusion Criteria:\n\n1. Age ≥ 18 years;\n2. Patients with non-valvular atrial fibrillation scheduled to undergo atrial fibrillation ablation and percutaneous left atrial appendage occlusion;\n3. Able to understand the purpose of the trial, willing to participate in the study, and the subject or their legal representative has signed the informed consent form, and is willing to complete the follow-up according to the protocol requirements.\n\nExclusion Criteria:\n\n1. Allergy to contrast agents or other conditions that preclude cardiac CT or DSA imaging;\n2. Absence of clear images for measuring the diameter of the LAA in all layers of the CT scan;\n3. Imaging indicates the presence of thrombus in the left atrium or LAA;\n4. Patients with valvular AF (mechanical valve replacement or moderate to severe mitral stenosis combined with AF);\n5. LAA depth \\\u003C 15 mm, or LAA anchor zone diameter \\\u003C 10 mm or \\> 33 mm;\n6. Female patients of childbearing age planning to become pregnant during the follow-up period required by this study;\n7. Currently participating in another clinical trial of drugs or medical devices and has not yet completed the primary endpoints of that study, which may confound the results of this study or affect the participant's compliance with the follow-up;\n8. Other conditions that the investigator deems make the participant unsuitable for this study.",{"count":709,"type":22},238,[82],"This study is a prospective, multi-center, randomized controlled trial. The subjects are patients scheduled to undergo a combined procedure of atrial fibrillation (AF) ablation and left atrial appendage (LAA) occlusion. After signing the informed consent form, the subjects will be randomly assigned to either the cardiac Computed Tomography (CT) group or the Digital Subtraction Angiography (DSA) group. The operator will select the appropriate LAA occluder size for implantation based on different measurement methods. All subjects will undergo clinical follow-up before discharge and at 3 months postoperatively, as well as telephone follow-up 1-5 years after the surgery.",[26,28,116,85],[714,199,715,716],"Left atrial appendage closure","Pacifier-like occluder","Stroke prevention","2024-06-07",{"date":719,"type":40},"2024-06-12",{"date":721,"type":22},"2024-07",{"date":723,"type":22},"2031-07",{"name":725,"class":102},"First Affiliated Hospital of Shantou University Medical College",5]